Skip to main content

JAK/TYK2

    RT @Yuz6Yusof: #OP0236 #EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo s
    1 year 9 months ago
    #OP0236 #EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo suppressed autophagy, increased apoptosis, and reduced expression of adhesion molecules in #sjogren salivary glands. Next step should be randomised controlled trial @RheumNow https://t.co/dirmHY9cYJ
    RT @doctorRBC: Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of an
    1 year 9 months ago
    Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of ankylosing spondylitis pts. Note 100% fatigue resolution roughly same vs. placebo @RheumNow #EULAR2022 ABST#POS0305 https://t.co/Doep91QIRa
    RT @doctorRBC: Upadacitinib effective in treatment of ankylosing spondylitis pts refractory to biologic tx - phase 3 tri
    1 year 9 months ago
    Upadacitinib effective in treatment of ankylosing spondylitis pts refractory to biologic tx - phase 3 trial Primary endpoint (ASAS40) and secondary endpoints met No malignancy, MACE, VTE, death @RheumNow #EULAR2022 ABST#POS0306 https://t.co/UL4hUJ0rQV
    RT @Yuz6Yusof: #LB0002 #EULAR2022 An interesting study design looking at flare rate following withdrawal of drug after W
    1 year 9 months ago
    #LB0002 #EULAR2022 An interesting study design looking at flare rate following withdrawal of drug after WK12. Phase 3 RCT of Baricitinib in paediatric JIA showed 76% met ACR30 at WK12. The Double-blind withdrawal showed less patients on Bari flared vs PBO (17% vs 51%) @RheumNow https://t.co/T0mSDkoHJo
    RT @RichardPAConway: Ramanan et al Baricitinib in JIA. Double blind withdrawal study of prior responders. Earlier flare
    1 year 9 months ago
    Ramanan et al Baricitinib in JIA. Double blind withdrawal study of prior responders. Earlier flare with PBO vs bari (HR 0.24 [95%CI 0.13,0.45], p<0.001. Less flares with bari vs PBO (17.1% vs 50.6%) p<0.001 @RheumNow #EULAR2022 LB0002 https://t.co/22rp70njRu https://t.co/LtJE9dz0GT
    RT @ericdeinmd: #EULAR2022 LB002
    P3 Double-Blind W/d study: Baricitinib for JIA
    ⭐️All pts start in open label w good
    1 year 9 months ago
    #EULAR2022 LB002 P3 Double-Blind W/d study: Baricitinib for JIA ⭐️All pts start in open label w good benefit (1/2 with ACR70) ⭐️PBO W/d led to 50% flare vs 17% in BARI group, flares earlier @RheumNow https://t.co/apSSLqu1mp
    RT @AurelieRheumo: JUVE-BASIS Baricitinib in JIA
    Phase 3 RCT wk12

    Cs or BioDMARDs IR

    ⚡️Time to disease flare HR 0.
    1 year 9 months ago
    JUVE-BASIS Baricitinib in JIA Phase 3 RCT wk12 Cs or BioDMARDs IR ⚡️Time to disease flare HR 0.24 ⚡️JIA-ACR50% 63% ⚡️% flares 17% vs. 50% in PBO Safety profile similar than adults @RheumNow #EULAR2022 LB0002 https://t.co/dX3DpB4QHT
    RT @drdavidliew: @EricFMorand up first in late-breakings
    PAISLEY: deucravacitinib (TYK2i) ph2 in SLE - add-on, steroid
    1 year 9 months ago
    @EricFMorand up first in late-breakings PAISLEY: deucravacitinib (TYK2i) ph2 in SLE - add-on, steroid wean Good outcomes: primary: SRI(4) at 32w skin/joint/LLDAS & dsDNA/C4 Safety good (like PsO/PsA) but higher dose less so Watch for: other clinical, ph3 #EULAR2022 @RheumNow https://t.co/XOQWuiHkTx
    RT @KDAO2011: Wow! Phase 2 #deucravacitinib data for #SLE met primary &amp; secondary endpoints: SRI(4) response, BICLA,
    1 year 9 months ago
    Wow! Phase 2 #deucravacitinib data for #SLE met primary & secondary endpoints: SRI(4) response, BICLA, LLDAS, CLASI-50. AEs include: skin related events and UTIs but no increase in SIE, HZ, MACE/VTE @bmsnews LB0004 #EULAR022 @rheumnow https://t.co/bsKI0mixVT
    RT @RichardPAConway: Morand et al Tyk2i deucravacitinib in SLE. 48-week phase 2 RCT. SRI(4) PBO: 34.4%; DEUC 3 mg BID:
    1 year 9 months ago
    Morand et al Tyk2i deucravacitinib in SLE. 48-week phase 2 RCT. SRI(4) PBO: 34.4%; DEUC 3 mg BID: 58.2%, P =0.0006; DEUC 6 mg BID: 49.5%, P =0.021; DEUC 12 mg QD: 44.9%, P =0.078. BICLA, LLDAS, CLASI-50, active joint count also+ @RheumNow #EULAR2022 LB0004 https://t.co/MBPc9xQFvG https://t.co/n3GUwl0RtD